Pharmala Biotech Holdings Inc C.MDMA

Interesting trading today so far

[inviolablspirit]

Interesting to see the response against Pharmala stock after the FDA Panal review board gave a negative recommendation and Optimi is so far untouched by the news.  Nick made it clear in the last interview that Pharmala will not be doing business in the US because if MDMA gets approved by the FDA then Lykos gets exclusivity in the US for the next 5 years anyways, so this FDA recommendation should have little effect on Pharmala.   His focus is the other countries (i.e. currently Australia and Canada), but because Pharmala's patented MDMA derivatives do address some of the safety risk concerns brought up by the FDA panal regarding cardiovascular issues this actually makes Pharmala even more valuable to big pharma as Pharmala's MDMA molecule is patented and therefore money can be made for big Pharma with the rights to this drug.  Clinical trials with Pharmala's MDMA molecule could now open the door for this company to be the MDMA molecule of choice for approval in the US.  Pharmala actually just became more valuable.  Those who sold may regret the sell.

[inviolablspirit]

For those that watched the FDA advisory panel yesterday will know that the cardiovascular risks like high blood pressure and heart rate were a major concern by the panal and Pharmala's MDMA patented molecule addresses that concern.  Their studies have shown significant reduction in that area.  I would think Nick should actually have more leverage in obtaining a partnership with a

[polygraph46]

invispirit: Very well said, re: your last couple of posts. While I did not watch the FDA panel yesterday, your off takes and views are, in my opinion, solid. We are in on the ground floor, Australia and here in Canada.  I believe in the CEO Nick K. and  the direction he is taking Pharmala. Thanks, pg

[inviolablspirit]

Thanks!  I did watch the entire review.   I just find it odd to see such an overeaction to a recommendation from a panel that doesn't really have any direct effect on where Pharmala is currently doing business.  The US is not Pharmala's focus as clearly stated by Nick in the last interview.  I'm sure FDA approval may speed up approval in other countries, but other